Upgrade to SI Premium - Free Trial

Spyre Therapeutics (SYRE)

100.81 +0.82 (0.82%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Spyre (SYRE) PT Raised to $120 at Mizuho July 13, 2026 6:44 AM - StreetInsider Form 4 Spyre Therapeutics, Inc. For: Jul 01 Filed by: Burrows Scott L July 2, 2026 9:34 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Jul 01 Filed by: Sloan Sheldon July 2, 2026 9:33 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Jul 01 Filed by: Turtle Cameron July 2, 2026 9:32 PM - SEC Filing Spyre Therapeutics Announces Grants of Inducement Awards July 2, 2026 4:05 PM - Globe NewsWire Form 144 Spyre Therapeutics, Inc. Filed by: Turtle Cameron July 1, 2026 5:02 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Jun 25 Filed by: Burrows Scott L June 26, 2026 9:32 PM - SEC Filing Spyre Therapeutics (SYRE) files mixed shelf June 26, 2026 4:09 PM - StreetInsider Form S-3ASR Spyre Therapeutics, Inc. June 26, 2026 4:06 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L June 25, 2026 4:03 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: Fairmount Funds Management LLC June 23, 2026 9:58 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Jun 23 Filed by: Fairmount Healthcare Fund II L.P. June 23, 2026 9:56 PM - SEC Filing Form SCHEDULE 13D/A Spyre Therapeutics, Inc. Filed by: Fairmount Funds Management LLC June 23, 2026 9:45 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Jun 22 Filed by: HENDERSON MICHAEL THOMAS June 23, 2026 9:33 PM - SEC Filing Spyre (SYRE) PT Raised to $135 at Deutsche Bank June 23, 2026 7:18 AM - StreetInsider Form 144 Spyre Therapeutics, Inc. Filed by: HENDERSON MICHAEL THOMAS June 22, 2026 4:45 PM - SEC Filing Guggenheim says buy this biotech stock June 18, 2026 4:00 PM - StreetInsider Spyre (SYRE) PT Raised to $104 at Jones Trading June 16, 2026 7:40 AM - StreetInsider Form 8-K Spyre Therapeutics, Inc. For: Jun 15 June 15, 2026 8:02 AM - SEC Filing Spyre reports positive phase 2 trial results for ulcerative colitis drug June 15, 2026 8:01 AM - StreetInsider Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients June 15, 2026 8:00 AM - StreetInsider Spyre Therapeutics Announces Grants of Inducement Awards June 5, 2026 4:01 PM - Globe NewsWire Spyre (SYRE) PT Raised to $115 at Deutsche Bank June 4, 2026 4:10 AM - StreetInsider Form 4 Spyre Therapeutics, Inc. For: Jun 03 Filed by: Sloan Sheldon June 3, 2026 9:32 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Jun 01 Filed by: Turtle Cameron June 3, 2026 9:31 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Jun 01 Filed by: Burrows Scott L June 3, 2026 9:31 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: Sloan Sheldon June 3, 2026 4:28 PM - SEC Filing Spyre completes enrollment in SKYWAY trial for anti-TL1A therapy SPY072 June 3, 2026 8:03 AM - StreetInsider Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA June 3, 2026 8:00 AM - StreetInsider Form 8-K Spyre Therapeutics, Inc. For: May 29 June 1, 2026 4:03 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: Kiselak Tomas May 29, 2026 5:58 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: Albers Jeffrey W. May 29, 2026 5:56 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: HENDERSON MICHAEL THOMAS May 29, 2026 5:56 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: Stelzer Laurie May 29, 2026 5:55 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: McKenna Mark C. May 29, 2026 5:55 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: Milligan Sandra May 29, 2026 5:55 PM - SEC Filing Form 8-K Spyre Therapeutics, Inc. For: May 27 May 29, 2026 4:46 PM - SEC Filing Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation May 28, 2026 8:35 AM - StreetInsider Spyre Therapeutics to Participate in Upcoming June Investor Conferences May 26, 2026 4:10 PM - StreetInsider Form 4 Spyre Therapeutics, Inc. For: May 08 Filed by: HENDERSON MICHAEL THOMAS May 8, 2026 9:32 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: HENDERSON MICHAEL THOMAS May 8, 2026 4:23 PM - SEC Filing Spyre (SYRE) PT Raised to $107 at Stifel May 5, 2026 4:26 PM - StreetInsider Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c May 5, 2026 10:20 AM - StreetInsider Form 8-K Spyre Therapeutics, Inc. For: May 05 May 5, 2026 8:05 AM - SEC Filing Form 10-Q Spyre Therapeutics, Inc. For: Mar 31 May 5, 2026 8:01 AM - SEC Filing Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update May 5, 2026 8:00 AM - Globe NewsWire Form 4 Spyre Therapeutics, Inc. For: May 01 Filed by: Burrows Scott L May 1, 2026 9:35 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 01 Filed by: Sloan Sheldon May 1, 2026 9:35 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 01 Filed by: Turtle Cameron May 1, 2026 9:34 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: Sloan Sheldon May 1, 2026 4:45 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L May 1, 2026 4:45 PM - SEC Filing Spyre Therapeutics Announces Grants of Inducement Awards May 1, 2026 4:28 PM - Globe NewsWire Full Article List